The Role of DigniCap in Reducing Chemotherapy-Induced Hair Loss

For individuals facing a breast cancer diagnosis, the prospect of chemotherapy-induced hair loss can be a difficult aspect of treatment. However, advancements in medical technology offer hope, providing options to mitigate hair loss and preserve a sense of dignity during a challenging time. One such innovation is the DigniCap Scalp Cooling System, FDA-cleared for patients with solid tumors. 

Scalp cooling is a clinically proven way to minimize chemotherapy-induced alopecia and help patients retain hair during treatment. By lowering a patient's temperature, less blood flows to the scalp. Consequently, less chemotherapy is able to reach the hair cells. The cells that do not receive a full dose of chemotherapy are more likely to survive treatment.

How DigniCap Works:

The DigniCap Scalp Cooling System consists of a computerized cooling unit managed through a touch-screen display and an attached cooling cap. Temperature-regulated coolant continuously circulates through specially designed channels in the cooling cap. The ability to maintain continuous, direct contact between the cooling cap and scalp for a consistent treatment temperature is a key factor in DigniCap's effectiveness. 

Scalp cooling requires a 30-minute pre-infusion cooling time to prepare the scalp before chemotherapy administration. Following the infusion, the scalp cooling treatment continues for a cycle of post-infusion cooling, typically lasting 60 to 180 minutes, depending on the drug and dose. By maintaining a reduced scalp temperature during and after chemotherapy, DigniCap maximizes its efficacy in minimizing hair loss.

Talk to your healthcare provider to learn more and see if DigniCap is right for you.